Metabolic Efficiency of Combined Pancreatic Islet and Lung Transplant for the Treatment of End-Stage Cystic Fibrosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

14 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-02-25

Study Completion Date

2019-12-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with end-stage cystic fibrosis (CF) and severe CF-related diabetes (CFRD) may benefit from combined lung-pancreatic islet transplantation. A recent case series showed that combined bilateral lung and pancreatic islet transplantation is a viable therapeutic option for patients with end-stage CF and CFRD. The use of different organs from a single donor may lead to reduced immunogenicity. As the prevalence of CFRD has increased dramatically with the improved life expectancy of patients with CF, islet transplantation should be considered at the end-stage CF. By restoring metabolic control, the investigators hypothesize that islet transplantation may improve the management of CF patients undergoing lung transplant and decrease the complication rate in the early postoperative period.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Lung Transplantation for Pleuroparenchymal Fibroelastosis

NCT05044390

Fibroelastosis

UNKNOWN

Non-respiratory Comorbidities Observed in Pulmonary French Transplant Patients With Cystic Fibrosis

NCT03357913

Pulmonary Failure Cystic Fibrosis

COMPLETED

Needs in Education for Pulmonary or Cardiopulmonary Transplanted Cystic Fibrosis Patients

NCT01285895

Cystic Fibrosis

COMPLETED

Extracorporeal Photopheresis in Lung Transplant Rejection for Cystic Fibrosis (CF) Patients

NCT03500575

Lung Transplant Rejection

UNKNOWN NA

Genetics of Insulin and Incretins in Cystic Fibrosis

NCT01852448

Cystic Fibrosis

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cystic Fibrosis Diabetes Related Cystic Fibrosis Insulin-dependent Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patient with cystic fibrosis

Patients with end-stage cystic fibrosis

Group Type EXPERIMENTAL

Combined pancreatic islet and lung transplantation

Intervention Type PROCEDURE

Combined pancreatic islet and lung transplant from the same donor for the treatment of patients with end-stage cystic fibrosis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Combined pancreatic islet and lung transplantation

Combined pancreatic islet and lung transplant from the same donor for the treatment of patients with end-stage cystic fibrosis

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with cystic fibrosis
* Patient able to respect the protocol procedures
* Patient with end-stage respiratory insufficiency indicating a lung transplant
* Clinical history of cystic fibrosis related diabetes and/or insulin-dependent diabetes, with no residual insulin secretion (C-peptide \< 0,5 ng/mL) and/or no response to IV glucagon stimulation: \[peak stimulated C-peptide (T6min)/basal plasma C-peptide(T0)\] \< 2. The absence of insulin secretion will be verified 2 times before inclusion
* Evolution of diabetes for over 3 years
* Patient whose glycaemic control obtained with insulin therapy is not satisfactory and could significantly alter quality of life (HbA1c \> 7% and/or MAGE index \> 1,25). This situation is assessed by a diabetologist.
* Social Security membership or benefit from Social Welfare
* Patient who received the results of the medical evaluation required

* Patient with contra-indication for undergo a lung transplant
* Patient with an indication of heart, liver or kidney transplantation
* Patient for which poor therapeutic compliance is expected
* Patient under oral antidiabetic drug
* In women of childbearing potential: pregnancy test (urine and / or blood) positive, lactation, or unwilling to use effective contraception for the duration of the study until 3 months after the end . Men: procreation project during the study period up to 3 months after its end, or unwilling to use effective contraception patient.
* Active infection, including hepatitis B, hepatitis C, HIV
* Any history of malignancy within the past 5 years, with the exception of cutaneous basal cell carcinomas completely resected. The history of breast or melanoma cancers are an absolute contraindication
* Alcoholic intoxication or drug addiction
* Anemia (hemoglobin Hb \<10g / dL in women and Hb \<11 g / dL in men), lymphopenia (\<1000 / uL), neutropenia (\<1500 / uL) or thrombocytopenia (\<100,000 / uL).
* Persistent elevated liver enzymes at baseline
* Portal hypertension identified by oesophageal varice and/or hypersplenism (platelets \< 120 000 /mm3) or Child-Pugh score \> 6.
* Use of a medical treatment under investigation within 4 weeks before inclusion
* All medical situation assessed by an investigator which could interfere with the good management of the project
* Patient restricted of freedom or unable to give his consent
* Patient has been included in another study that could interfere with the results of the study
* Contraindications to the use of experimental drugs (Cellcept®, prednisone, Prograf, prednisolone, methylprednisolone, and pancreatic islets)

Minimum Eligible Age

14 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No